美国VeroScience研究中心神经生理学研究博士后职位

VeroScience is a small but very well developed biotechnology company focusing on neuroendocrine therapies for metabolic and immunological diseases.  The company developed and owns Cycloset®, an FDA-approved therapy for the treatment of type 2 diabetes. VeroScience also has a strong pipeline of metabolic disease products and therapies for immunological disorders.  The company is a hybrid of academic environment mindset and industrial focus within a small and efficient organization.  The company conducts preclinical and clinical research nation-wide, utilizing strong academic and pharmaceutical industry collaborations to advance its development programs.